Object. Heparin-induced thrombocytopenia Type II (HIT II) is a serious complication that occurs in 0.2-3% of patients treated with heparin and is associated with a high risk of thrombotic events. One center recently reported an incidence of HIT II of 15% in a population of patients with aneurysmal subarachnoid hemorrhage (aSAH). Because these patients are typically exposed to heparin during angiography, controversy exists regarding whether prophylaxis with enoxaparin rather than heparin affords any reduction in the risk of developing HIT II. In this study, the authors investigated the effect of heparin compared with enoxaparin on the incidence of HIT II in patients with aSAH.
H eparin-induced thrombocytopenia is a potentially life-threatening complication of heparin exposure, and has been classified into 2 forms. Heparininduced thrombocytopenia Type I, the clinically benign form, is characterized by a mild fall in platelet count (100,000-150,000/µl) that typically occurs within several days of heparin exposure and returns to normal levels despite continued exposure. 51 Heparin-induced thrombocytopenia Type I is asymptomatic, and its mechanism is believed to be due to a self-limited, direct effect of heparin on platelet aggregation. 5, 10, 11, 24 The more perilous form, HIT II, is characterized by a significant reduction in platelets (< 100,000/µl or < 50% of baseline) and a substantial risk for severe thrombotic events. 9, 15, 44, 54, 57 Heparin-induced thrombocytopenia Type II occurs in ~ 0.2-3% of patients treated with heparin 23, 29, 39, 46, 54 and typically occurs 5-10 days after heparin exposure. 53 This disorder is autoimmune in nature and is instigated by antibodies directed against complexes that form between heparin or other anionic mucopolysaccharides and platelet factor 4, a heparin-binding protein released by activated platelets. 3, 13, 14, 27, 32 These heparinplatelet factor 4 antibody complexes then bind to the surface of platelets, leading to their activation (promoting thrombosis) and clearance (leading to thrombocytopenia).
botic risk in these patients is > 30 times that in control populations, 23 and in patients who present without thrombosis, its risk persists for days to weeks, with up to 50% eventually experiencing a thrombotic event.
52 Possible complications include stroke, myocardial infarction, pulmonary embolism, DVT, limb amputation, and death. The mortality rate of patients with HIT II is 8-20% and the rate of limb amputation is 5-10%. 34, 37 The widespread use of endovascular procedures in patients with aSAH, which requires heparin anticoagulation, has warranted concern for increased risk of HIT II in this patient population. A single-center study recently reported the incidence of HIT II to be 15% in a population of patients with aSAH. 30 In comparison, in the population undergoing orthopedic surgery, the group previously considered to be at highest risk for HIT II, the incidence of the disease has been reported to be only as high as 5.2%. 25, 40, 56 In light of this alarmingly high incidence of HIT II in patients with aSAH, we have increasingly relied on alternate anticoagulant therapy, namely enoxaparin, for thromboprophylaxis. Previous studies have shown that LMWH, when compared with heparin, reduces the risk of HIT II and subsequent thrombosis in patients undergoing neurological, orthopedic, and cardiac surgery. 21, 25, 29, 35, 38, 42, 43, 54 Two prospective studies from the orthopedic literature have reported HIT II incidences of 0 versus 5.2%
25 and 0.6 versus 4.8% 55 in enoxaparin-treated compared with heparin-treated patients. In the neurosurgical patient population, however, no group to date has investigated the effectiveness of replacing heparin with LMWH in decreasing the risk of HIT II. In fact, descriptions of HIT II in the neurosurgical literature remain sparse. For patients with aSAH, in particular, the use of LMWH rather than heparin for thromboprophylaxis may not offer a similar benefit, due to routine exposure of these patients to heparin during their treatment.
In this study we sought to determine the incidence of HIT II in our own population of patients with aSAH. We also compared the incidences of HIT II in patients treated with heparin and in those treated with the LMWH enoxaparin. We hypothesized that replacement of heparin with enoxaparin for thromboprophylaxis in patients with aSAH would prove ineffective in deterring the development of HIT II, due to routine exposure of all patients with aSAH to heparin during diagnostic cerebral angiography.
Methods

Patient Population
Three hundred ninety-seven consecutive patients were treated for aSAH at Columbia University Medical Center between January 2002 and December 2005. Three hundred eighteen patients received thromboprophylaxis after aneurysm treatment (79 patients did not receive thromboprophylaxis for various reasons, including early death, early ambulation, and refusal). Eighteen patients received both heparin and enoxaparin prophylaxis during their hospital stay and were excluded from the study. In total, 300 patients (85 men and 215 women; age 53 ± 14 years [mean ± SD]) were included in the analysis (Table 1) .
Subarachnoid hemorrhage was diagnosed based on admission CT scans or by lumbar puncture if the CT was nondiagnostic. Intracranial aneurysm was confirmed by 4-vessel cerebral angiography in all patients.
Patient demographic, clinical, and radiographic data were prospectively collected in an SAH patient database. Patient laboratory data, pharmacy orders, and adverse hospital events were retrospectively collected from the patients' medical records. This study was approved by the Columbia University Medical Center Institutional Review Board.
Clinical Management
A standardized protocol was used in the management of all cases of aSAH. All patients with aSAH treated at our center are immediately admitted to the Neurological ICU, where they undergo aggressive resuscitation, intraarterial blood pressure monitoring, and daily blood chemistry panels as well as platelet and cell counts. All patients receive a peripheral arterial line and a central venous line, which are flushed with nonheparinized saline according to protocol to maintain catheter patency.
Patients undergo diagnostic angiography and aneurysm repair within 24 hours of admission, whenever possible. Decisions regarding the modality and timing of treatment are made by an interdisciplinary team, including a neurosurgeon, interventional neuroradiologist or endovascular surgeon, and neurointensivist. After aneurysm repair, patients receive thromboprophylaxis with either heparin (5000 IU every 12 hours intramuscularly) or enoxaparin (40 mg daily intramuscularly). During cerebral angiography, the sheath and catheter are constantly flushed with a heparinized saline solution (3000 IU of heparin in 1000 ml of normal saline). Patients who undergo endovascular coil embolization procedures receive a 4000-5000 IU heparin bolus at the beginning of the procedure, followed by a heparin infusion during and for 24 hours after the procedure.
Diagnostic Criteria for HIT II
The diagnosis of HIT II was determined retrospectively according to previously described clinical criteria 7, 9, 30, 31, 39, 51, 53 and required the following: 1) thrombocytopenia, defined as platelet count < 100,000/µl or < 50% of baseline (patient's platelet counts were measured daily and the count on admission was regarded as baseline); 2) thrombocytopenia within 4-14 days of admission; 3) the exclusion of other potential causes of thrombocytopenia such as infection, drug-mediated or other autoimmunemediated processes, and multiple myeloma or other blood dyscrasias; and 4) the resolution of thrombocytopenia after the discontinuation of heparin therapy.
Statistical Analysis
Chi-square tests were used for between-group comparisons of categorical data. The Fisher exact test was used where appropriate. Unpaired Student t-tests were used for between-group comparisons of continuous data. We compared the risk of developing HIT II in patients who received heparin prophylaxis and in those who received enoxaparin prophylaxis, expressed as a risk difference and as a risk ratio. We estimated that we would require 128 patients in each treatment group to detect an HIT II incidence difference of 4.2% between the 2 groups, with a power of 80% and a 2-sided alpha value of 0.05. 55 Statistical analyses were performed using commercially available software (SPSS version 13.0, SPSS Inc.). A probability value of < 0.05 was considered significant for all analyses; all tests were 2-sided.
Results
Patient Cohort Characteristics
The mean age of the total patient cohort was 53 ± 14 years (mean ± SD). Eighty-five patients (28%) were male, and 215 (72%) were female. These patient characteristics are representative of the general population of patients with aSAH. 33 Seventy-three patients (24%) presented with Hunt and Hess Grades IV and V, and 194 patients (65%) presented with Fisher Grades 3 and 4. Two hundred sixty-six patients (65%) had anterior circulation aneurysms, and 63 (12%) of these were > 10 mm in diameter. Two hundred forty patients (80%) were treated surgically, 52 (17%) were treated endovascularly, and 8 (3%) received both endovascular and open surgical treatment.
Incidence of HIT II
Sixteen patients (5.3%) of the total patient cohort met the diagnostic criteria for HIT II. The mean platelet count nadir in the 16 patients with HIT II was 85,250 ± 33,300/ μl (mean ± SD), compared with the mean platelet count nadir in the 284 patients with aSAH and without HIT II, which was 202,600 ± 72,700/μl (p < 0.001) ( Table 1) . Patients affected by HIT II were more likely than patients without HIT II to present with Hunt and Hess Grades IV and V (p < 0.01); conversely, patients without HIT II were more likely to present with Hunt and Hess Grades I-III (p < 0.01). Patients with HIT II and those without were comparable in terms of age, sex, ethnicity, Fisher grade, and aneurysm size and location, as well as aneurysm treatment type (Table 1) .
Fifteen (94%) of the 16 patients with HIT II encountered thrombotic complications (Table 2) . Three patients (19%) died of complications. The mean interval to thrombocytopenia for the patients with HIT II was 6 days after admission.
Comparison of Heparin-and Enoxaparin-Treated Patients
One hundred sixty-six patients (55%) received heparin prophylaxis, and 134 (45%) received enoxaparin prophylaxis. In Table 3 we compare the demographic, clinical, and radiographic characteristics between the 2 treatment groups. There were no significant differences in any of these characteristics. The mean platelet count nadir in patients treated with heparin was 205,500 ± 77,300/μl, compared with 185,100 ± 72,700/μl in patients treated with enoxaparin (p = 0.02).
Of the 166 patients treated with heparin, 8 (4.8%) developed HIT II, and of the 134 treated with enoxaparin, 8 (6%) developed HIT II. There was no significant risk difference between the 2 treatment groups (risk difference of 1.2%, 95% confidence interval for risk difference −7.0 to 4.1%; relative risk 0.81, 95% confidence interval for relative risk 0.31-2.09).
Discussion
The neurosurgical patient population is among those with the highest risk for thromboembolic complications. The incidence of DVT in neurosurgical patients has been reported to be 19-50% when measured by radiolabeled fibrinogen testing. 1, 20, 28 Relying on clinical diagnosis, DVT was found to occur in 2.3% of patients, with 1.8% developing pulmonary emboli. 6 The death rate from DVT in the lower extremities has been reported to be as high as 50%. 28 There are many randomized trials showing an important reduction of DVT when heparin prophylaxis is used in patients undergoing orthopedic, urological, and general surgery procedures. On the other hand, because of concerns about postoperative intracranial bleeding, only a few studies have been reported in the neurosurgical literature.
In the 2 largest studies, the risk of DVT was found to outweigh the risk of intracranial hemorrhage, and thus, the use of heparin prophylaxis was advocated. 8, 22 Neurosurgical patients are at considerable risk of developing HIT II and its complications as well. According to the American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy, neurosurgical patients meet criteria placing them in the highest risk group for HIT, a risk > 1%. 51 These criteria include postoperative status and the use of indwelling catheters flushed with unfractionated heparin. Recommendations in this group are to check platelet levels on a daily basis.
The diagnosis of HIT II relies on both clinical context and laboratory values. The accepted diagnostic criteria cited by the American College of Chest Physicians Conference are as follows: 1) thrombocytopenia that occurs 4-14 days after beginning heparin therapy, defined as a platelet reduction to < 100,000 or < 50% of baseline; 2) exclusion of other causes of thrombocytopenia; and 3) resolution of the thrombocytopenia with cessation of heparin therapy. We based our definition of HIT II on these diagnostic criteria for 2 reasons: first, they are the primary means of diagnosing HIT II established by the current literature;
18,51 and second, they match the criteria used in a previous study of HIT II in the population with aSAH by Hoh et al., 30 facilitating a direct comparison of our observations.
Heparin-induced thrombocytopenia in the neurosurgical patient population has been infrequently reported. The literature consists of 3 case reports and 1 retrospective study. The first publication, appearing in 1986, documented 2 cases of HIT acquired from heparin exposure through heparinized indwelling catheters. 17 Rogers et al. 45 in 1988 described a case of HIT following heparin flushing during reported on a patient with aSAH in whom HIT developed due to heparin flushing of indwelling catheters.
Only one large-scale study has examined the incidence of HIT II in patients with aSAH. This retrospective study by Hoh et al. 30 in 2005 documented an alarmingly high rate (15%) of HIT II associated with heparin exposure in a cohort of 389 patients with aSAH examined between 2000 and 2003. The investigators found that the development of HIT II was associated with female sex and Fisher Grade 3 on admission, and they demonstrated an association of HIT II with an increased rate of new hypodensities on CT scans (66 vs 40%), lower rate of favorable outcome (38 vs 52%), and increased mortality rate (29 vs 12%). The authors suggested that the far higher incidence of HIT II in their patient population with aSAH, compared with other surgical populations, was attributable to exposure to heparin during endovascular procedures and from heparinized indwelling catheters in the ICU.
It is possible that the different heparin exposure between those treated with coils versus clipping therapy combined with the relative paucity of coil embolization procedures in our study may explain the decreased incidence of HIT II.
In light of this increasing awareness of the risk of HIT II in the population of patients with aSAH, in 2003 we began routinely administering enoxaparin rather than heparin for thromboprophylaxis after treatment for aSAH. Numerous studies in other patient populations have shown that the incidence of HIT II is decreased in LMWH-treated patients compared with heparin-treated patients. 4, 16, 23, 25, 36, 48, 50, 56 In the population studied after undergoing orthopedic surgery, the demonstration of an especially high rate of heparin-related HIT II in conjunction with 2 studies showing a lower incidence of HIT II in enoxaparin-treated patients compared with heparin-treated patients (0 vs 5.2%
25 and 0.6 vs 4.8% 55 ) have led to recommendations against the use of heparin in this population.
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In addition, a recent cost analysis of heparin versus enoxaparin used for DVT prophylaxis in medical patients found that although LMWH costs ~ 10 times what heparin does per patient, it conveys both a morbidity/mortality benefit as well as an overall cost benefit of $13.88 per patient. 16 A separate cost analysis performed in Germany compared the use of heparin and enoxaparin in patients undergoing orthopedic surgery and found that enoxaparin was both more cost effective and decreased life-years lost. 47 No group to date, however, has evaluated the effectiveness of replacing heparin with enoxaparin in decreasing the risk of HIT II in the population of patients with aSAH.
We therefore conducted a retrospective analysis over a 4-year period in our population of patients with aSAH to document the incidence of HIT II in response to heparin versus enoxaparin. The rate of HIT II that we observed in our patients with aSAH was much lower than that cited by Hoh et al. 30 (5.3 vs 15%) and more consistent with the rate of HIT II reported in medical patients (< 1-5%) 19 and surgical patients (1-5.2%). 25, 56 The rate of HIT II in heparintreated patients in our study was 4.8%, compared with 6% in enoxaparin-treated patients.
There are several factors that could possibly explain the much lower incidence of HIT II in our study. First, although all of our patients with aSAH receive heparin routinely during angiography, our patients' vascular catheters are not maintained with heparinized saline while in the ICU, compared with the previous study. Second, Hoh et al. 30 report that 61% of their patients with HIT II received endovascular treatment (they do not report percentage of total study group) compared with only 13% in our HIT II patients and 17% in our total patient cohort. Greater usage of endovascular coil embolization in addition to maintenance of lines with heparin may have led to greater patient exposure to heparin and conceivably to a higher incidence of HIT II.
In our study, the rate of HIT II in heparin-treated patients was not statistically different from that observed in enoxaparin-treated patients (4.8 vs 6%). A power analysis based on rates of HIT II in a randomized clinical trial comparing enoxaparin (0.6%) to heparin (4.8%) in orthopedic patients showed that a total of at least 128 patients in each group would adequately demonstrate this difference. 55 With a total of 300 patients (134 enoxaparintreated and 166 heparin-treated patients), our study was adequately powered to show the same difference demonstrated in the patient population undergoing orthopedic surgery, in which the same criteria for HIT II were used. Equal rates of HIT II between heparin-and enoxaparintreated patients may be explained by the fact that at our institution all neurosurgical patients are exposed to heparin during cerebral angiography. This exposure to heparin, then, would negate any potential benefit of subsequent selection of enoxaparin over heparin in the reduction of the risk of developing HIT II.
There have been multiple documented cases of patients developing HIT II from short-term, minimal exposure, such as through indwelling vascular catheters flushed with heparin, or even heparin-coated catheters, supporting the conclusion that replacing enoxaparin with heparin must be an all-or-nothing change in protocol. 2, 41 Therefore, the only way to measure effectively any clinical benefit gained from the continued use of enoxaparin for thromboprophylaxis in lieu of heparin in the population of patients with aSAH is by completely eliminating heparin from both indwelling catheters and cerebral angiography. A more rigorous cost/benefit analysis of the complete elimination of heparin from use among patients with aSAH is necessary to evaluate the practicality of such a measure.
Conclusions
In this study, we found that the rate of HIT II among patients with aSAH may actually be lower than previously reported (5.3 vs 15%) . We have also shown that using enoxaparin in the place of heparin for thromboprophylaxis in patients already exposed to heparin has no therapeutic benefit. Our study, however, is based on a retrospective review, and future prospective studies may offer additional insight on the rate of HIT II in this population. In light of our findings and the much higher cost of enoxaparin, we conclude that it is reasonable to use heparin rather than enoxaparin for thromboprophylaxis in patients with aSAH. 
